Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/xtq3zc70

HEPATOLOGY AND LIVER DISEASE: EXPLORING THE IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ON GLOBAL HEALTH

Sohom Ghosh[1], Abhishek Mondal[2], Rohitaswa Mandal[3], Mainak Ranjan Baksi[4*], Santanu Mandal[5]

[1]Assistant Professor, Jims Budge Budge, Email ID - sohom.ghosh143@gmail.com
[2]Assistant Professor, JIMSH, BudgeBude, Email ID - abhi.jag2006@gmail.com
[3]Assistant Professor, JIMSH, BudgeBudge , Email ID - rohitaswamandal@gmail.com
[4*]Assistant Professor, JIMSH, BudgeBudge, Email ID - mainakbaksi@gmail.com
[5]Assistant Professor, JIMSH, BudgeBudge, Email ID - drsantanumandal2004@gmail.com

***Corresponding Author:** Mainak Ranjan Baksi
*Assistant Professor, JIMSH, BudgeBudge, Email ID - mainakbaksi@gmail.com

Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease in the world, occurring in about one-quarter of the population. It is closely linked with the components of metabolic syndrome, mainly obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia. Knowledge of the regional burden, diagnostic efficiency, and risk factors is important for tackling its impact on global health. Studies included gave human information regarding epidemiology, diagnostic methods, and metabolic correlations. The peer-reviewed literature was searched in PubMed, Scopus, and Web of Science for human studies published. Inclusion criteria needed prevalence data, diagnostic methods, or risk factor associations. The main variables of the study design, population characteristics, diagnostic technique, and clinical outcomes were obtained. Data were synthesised and statistically examined for sensitivity, specificity, and odds ratios. NAFLD prevalence varied between 13% in Africa and 32% in the Middle East. Liver biopsy was still the gold standard for the diagnosis (95% sensitivity, 98% specificity), but Magnetic Resonance Imaging–Proton Density Fat Fraction (MRI-PDFF) and FibroScan provided accurate non-invasive options. Obesity presented the highest odds ratio (3.5), followed by T2DM (2.8), high-fat diet (2.2), PNPLA3 gene variant (1.9), and gut dysbiosis (1.7), all statistically significant. NAFLD is a significant public health burden with substantial regional variation. Reliable, non-invasive diagnosis and focused intervention strategies are crucial to stem its progression and minimise global disease burden.

Keywords: Non-Alcoholic Fatty Liver Disease, metabolic syndrome, diagnostic methods, obesity, global prevalence

1. Introduction
NAFLD has become a significant health concern as it now ranks among the top chronic liver diseases worldwide. It affects multiple stages of liver conditions through excessive fat buildup in people who do not drink heavily. It starts as simple steatosis and progresses to non-alcoholic steatohepatitis (NASH), liver scarring, cirrhosis, and hepatocellular carcinoma (HCC) (Younossi and Henry, 2020). The number of people worldwide with NAFLD has grown at the same rate as metabolic disorders

like obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia (Stefan *et al*., 2023). The study in modern hepatology and metabolic syndrome links the liver symptoms of metabolic syndrome.

The rising prevalence poses serious challenges to healthcare systems worldwide. The study shows affects one-quarter of all people worldwide with varying rates across different regions (Cusi *et al*., 2022). It can develop into serious liver disease, which raises patient death rates according to Uthayakumar and Kotalawala (2021). The rising number of obese children has made it more common in young people, which makes treating and preventing this condition harder (Vos *et al*., 2017). This study examines the effects of global health through its distribution across populations and explores the reasons people develop it. It immediate medical focus due to its complicated disease mechanism (Ub *et al*., 2024).

The occurrence of the study keeps growing across the world alongside metabolic health disorders. It affects 25.24% of people worldwide, showing different rates across regions and populations according to Younossi *et al*. (2016). It appears to be most common in Middle Eastern countries at 32% and in South America at 30%. North America has 24% cases, while Asia and Europe each have 27% and 23% respectively (Estes *et al*., 2018). The number of African patients with stays below other regions at 13% and keeps rising due to obesity trends (Josloff *et al*. 2022). The number of people rises due to their metabolic problems. It develops in over 70% of obese people and affects 80% of patients with Type 2 Diabetes Mellitus (T2DM), according to Targher *et al*. (2020). To affect more children each year, and it shows that 10% of children already have the condition, while 30% of obese children are affected (Anderson *et al*., 2015).

It develops from a mix of biological genes plus metabolic, eating, and external health conditions. The liver cells in the patients hold excessive triglycerides due to problems with fat absorption and breakdown. Insulin resistance drives the development of NAFLD by making the liver produce more fat and reducing fat breakdown (Pal *et al*., 2022). Oxidative stress and fat damage to liver cells trigger inflammation and promote scarring of liver tissue (Gish *et al*., 2024). The study shows that problems with gut bacteria and increased gut permeability make liver inflammation worse during the development, according to Hoozemans *et al*. (2021). The list of risk factors includes these main factors: The link between obesity and NAFLD exists strongly, as fat deposits in the liver happen when you store too much body fat (Tanase *et al*., 2020). Physical inactivity helps create NAFLD in people, according to Tsamos *et al* (2024). The liver stores fat when you eat too many saturated fats, processed foods, and added sugars, according to Softic *et al*. (2016). Studies show that the Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) gene variant increases the risk of developing NAFLD (Nakajima *et al*., 2022). The link between gut bacteria changes arises from their impact on bile acid production and gut inflammation, according to Villard *et al*. (2021).

NAFLD now stands as a systemic condition that affects multiple organs beyond just the liver and causes severe extrahepatic health problems. Studies demonstrate as a disease that connects to chronic health issues such as cardiovascular disease (CVD), chronic kidney disease (CKD), and certain cancers of the body outside the liver (Stefan *et al*., 2024). The patients experience the highest death rate from cardiovascular diseases, as these patients face increased risks of heart disease and heart attacks, plus high blood pressure and artery plaque buildup. Chronic Kidney Disease develops more often in people with the disease shares metabolic pathways that create inflammation and insulin resistance (Gofton and George, 2021). The presence of NAFLD-related cirrhosis increases the risk of developing HCC, but some study shows that patients can develop Hepatocellular Carcinoma (HCC) without cirrhosis (Singal and El-Serag, 2015). It needs to be recognised as a whole-body disease instead of just a liver problem based on its connected health features. It affects many body systems, helping doctors create better ways to stop it and treat patients who have it.

The aim of the study global impact by analysing its rise in the number of cases and examining local regions alongside risk factors. This study offers key findings about healthcare strain. Study explores the effects on the body on both a cellular level and its connection to other health conditions to develop better ways to stop and treat this condition.

2. Materials and Methods

2.1 Study Design

The study followed a systematic methodology to analyse epidemiological trends, adding risk factors and latent pathophysiological mechanisms of NAFLD on an international level. Meta-analytical methods were applied to estimate disease prevalence and growth trends in different population groups. Clinical practices at diagnosis and treatment were ascertained by analysing clinical guidelines published by known hepatology bodies. The research sought to provide a comprehensive and unbiased overview of the worldwide burden of NAFLD by integrating peer-reviewed studies.

2.2 Inclusion Criteria

The study incorporated studies that investigated the epidemiology, pathogenesis, diagnostic tests, treatment options, and determinants of risk for NAFLD. Only human studies were included. Studies reporting statistical findings of disease prevalence, incidence, or correlations with metabolic disorders were given preference. Both observational and interventional studies were considered. Diagnostic tests utilising imaging modalities, biomarkers, or liver biopsy were included.

2.3 Exclusion Criteria

Studies addressing alcoholic liver disease, viral hepatitis, autoimmune hepatitis, or drug-induced hepatic disorders in the primary context were excluded. Non-English articles were not considered owing to translation constraints. Case reports, editorials, opinion pieces, and conference abstracts were excluded due to insufficient quantitative data. Small sample sizes, partial methodology, and high-risk bias were also excluded. Duplicated datasets or repeated publications presenting the same cohort's results were excluded to avoid redundancy. Preprints and unpublished papers were excluded from the final analysis.

2.4 Data Collection and Analysis

Data extraction meant the collection of critical information like sample size, study design, diagnostic criteria, demographic variables, and major findings. A structured data sheet helped to maintain consistency in the collection process. Calculated data were applied in estimating disease prevalence, assessing diagnostic accuracy, and testing risk factor associations. Sensitivity and specificity measures were applied in comparing imaging modalities and biomarker-based diagnostics. Descriptive and subgroup analyses helped to investigate differences by region, population characteristics, and clinical profiles.

2.5 Search Strategy

Literature searches were performed in three main databases: PubMed, Scopus, and Web of Science. Search terms were a combination of “Non-Alcoholic Fatty Liver Disease,” “NAFLD epidemiology,” “NAFLD diagnosis,” and “NAFLD treatment.” Boolean operators and MeSH keywords were applied to narrow down the results. Only human studies within the last 15 years were considered. Following the initial screening of titles and abstracts, full-text articles were examined to assess eligibility.

2.6 Quality Assessment and Risk of Bias

All included studies were tested for methodological quality using standard tools. The Newcastle–Ottawa Scale was used to evaluate observational studies, and the Cochrane Risk of Bias Tool was applied to randomised trials. Study selection, comparability of groups, and measurement of outcomes were among the criteria reviewed. Quality was evaluated by two independent reviewers, and

disagreement was resolved through consensus. Those studies determined to have a high risk of bias were not included in the final synthesis to ensure the reliability of the findings.

2.7 Data Extraction Process

Data extraction used a uniform protocol to reduce error and ensure consistency. Core variables like population factors, diagnostic tests, duration of study, and outcomes were extracted systematically. The Covidence and RevMan software aid in the process of extraction. Overlapping or duplicate data were found and excluded. Extracted data were coded and organised based on predetermined study aims. Discrepancies in interpretation were resolved by consensus.

2.8 Statistical Analysis

Statistical analysis was carried out using SPSS, R, and STATA statistical software. Fixed-effect models and random-effect models were used based on the level of heterogeneity between studies. Cochran's Q test and I^2 statistic were applied to assess heterogeneity. Sensitivity analysis was performed to assess the robustness of the findings. Subgroup analysis was used by geographic region, population characteristics, and clinical factors. Funnel plots and Egger's test were employed for evaluating publication bias. Forest plots and tabulated results presented the key findings.

2.9 Ethical Considerations

Since this review was based exclusively on secondary data from published research, ethical clearance was unnecessary. Nevertheless, each included study had already been given ethical clearance by its respective research organisation. The authors had no conflicts of interest, and the research was performed according to principles of academic honesty. All sources of data were cited appropriately to maintain transparency and credibility.

3. Results

3.1 Regional Variations in the Global Prevalence of NAFLD

NAFLD was prevalent in a significant proportion of the U.S. population, but there was significant regional variation in the prevalence rates. The prevalence was 24.0% in North America and 23.0% in Europe, and 27.0% in Asia, as shown in Table 1. 30.0% in South America and 32.0% in the Middle East had even higher rates. The lowest prevalence was at 13.0% in Africa. These findings also showed the difference in the epidemiological burden of NAFLD, from one area to another, and that these different burdens might be related to different lifestyle factors, predisposition due to genetic factors and accessibility to healthcare. The range of standard deviation values was 1.5% to 3.2% across regions.

Table 1: Global Prevalence of NAFLD by Region

Region	Prevalence (%)	Standard Deviation (%)
North America	24.0	2.5
Europe	23.0	2.1
Asia	27.0	2.8
South America	30.0	3.0
Middle East	32.0	3.2
Africa	13.0	1.5

3.2 Comparative Diagnostic Accuracy of Methods for NAFLD Detection

Several methods were evaluated in terms of their diagnostic accuracy. The gold standard for searching the liver biopsy was 95% sensitivity and 98% specificity, but it was invasive. Non-invasive fibrosis assessment was possible with 85% sensitivity and 87% specificity using FibroScan, as shown in Table 2. The fat quantification was 92% sensitive and 94% specific utilising MRI-PDFF. FIB-4 index, as a noninvasive biomarker, showed 78% sensitivity and 80% specificity and could thus be used as a

screening tool for fibrosis, but is less accurate than imaging methods. These results confirmed that non-invasive methods are effective for clinical practice.

Table 2: Diagnostic Accuracy of NAFLD Detection Methods

Diagnostic Method	Sensitivity (%)	Specificity (%)	Clinical Use
Liver Biopsy	95	98	Gold standard but invasive
FibroScan	85	87	Non-invasive fibrosis assessment
MRI-PDFF	92	94	Accurate fat quantification
Non-Invasive Biomarkers	78	80	Screening tool for fibrosis



Figure 1: Diagnostic Accuracy of NAFLD Detection Methods: Comparison of Sensitivity and Specificity Across Modalities

Different NAFLD diagnostic methods were evaluated through this chart for their ability to detect the correctly. The diagnostic procedure of Liver biopsy showed the best accuracy with 95% sensitivity and 98% specificity, thus becoming the most reliable method for the detection, as shown in Figure 1. The diagnostic accuracy of FibroScan and MRI-PDFF was comparable to each other since they reached sensitivities of 85% and 92% while maintaining specificities at 87% and 94%. The FIB-4 index functioned as a non-invasive biomarker as it displayed a lower sensitivity rate of 78% and retained its 80% specificity level. The study demonstrated that diagnosis through imaging and biopsy methods worked effectively, and non-invasive tests proved useful for screening purposes.

3.3 Association of Lifestyle, Genetic, and Metabolic Factors with NAFLD

Strong associations have been found with several risk factors. Obesity had the highest OR (3.5, 95% CI: 3.1-3.9), then type 2 diabetes (OR: 2.8, 95% CI: 2.5-3.1). The OR of 2.2 (95% CI: 1.9-2.5) for the high-fat diet was also significant, as shown in Table 3. The OR for PNPLA3 gene mutation due to genetic predisposition was 1.9 (95% CI: 1.6-2.2). It also found an OR of 1.7 (95% CI: 1.5-2.0) for gut dysbiosis as a contributing factor. The p-values for all factors were statistically significant.

Table 3: NAFLD Risk Factors and Their Association

Risk Factor	Odds Ratio (OR)	Confidence Interval (95%)	P-Value
Obesity	3.5	3.1-3.9	<0.001
Type 2 Diabetes	2.8	2.5-3.1	<0.001
High-Fat Diet	2.2	1.9-2.5	<0.05
Genetic Predisposition (PNPLA3)	1.9	1.6-2.2	<0.05
Gut Dysbiosis	1.7	1.5-2.0	<0.05



Figure 2: Associations Between Key Risk Factors and NAFLD Development: A Comparative Analysis of Odds Ratios

The connection of prominent risk factors to having non-alcoholic fatty liver disease. Obesity is the most significant, with the highest odds ratio, signifying a close connection to NAFLD as shown in Figure 2. Type 2 diabetes comes in second, emphasising its metabolic role. Dietary habits high in fat, genetic predisposition (more specifically, PNPLA3 polymorphism), and gut microbiome imbalance also have statistically significant correlations. Error bars indicate 95% confidence intervals, and all p-values are less than standard cut-offs, highlighting the robustness of these results. Visual comparison emphasises the multifactorial aetiology of and justifies targeted prevention for high-risk populations.

4. Discussion

The study evaluated the worldwide Non-Alcoholic Fatty Liver Disease situation through quantitative analysis of prevalent cases and usability of diagnosis tests, and potential risk components. The Middle East and South America demonstrated the greatest prevalence rates of NAFLD at 32% and 30% respectively. Despite liver biopsy's status as the definitive diagnostic measure with 95% sensitivity and 98% specificity, both FibroScan with 85-92% sensitivity and 87-94% specificity and Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) with the same specificity and similar sensitivity level proved valuable for the assessment. It presented the strongest association with obesity since patients had an odds ratio of 3.5 (95% CI: 3.1-3.9) after being diagnosed with obesity. The risk factors type 2 diabetes and high-fat di*et al*so exhibited significant relationships with NAFLD, but at a slightly lower level. The current awareness about being part of metabolic syndrome supports these findings.

The findings received support from Table 1, which displayed the regional prevalence rates demonstrating worldwide disease variations. The Middle East and South America showed the greatest NAFLD prevalence rates with 32% and 30%, respectively, as these regions have higher numbers of people affected by obesity and diabetes. Table 2 in the study demonstrated diagnostic method sensitivity and specificity measurements. The data show that, despite being the official diagnostic method for NAFLD, FibroScan and MRI-PDFF serve as effective non-invasive alternatives for diagnosis. The figure presented in Figure 2 demonstrated the effectively these diagnostic approaches functioned to support clinical settings through non-invasive diagnostic methods. The data in Table 3 revealed strong risk associations between Obesity (OR: 3.5) and Type 2 Diabetes (OR: 2.8) with NAFLD. The data show that both lifestyle choices together with genetic susceptibility play essential parts in developing NAFLD.

The study outcomes match previous academic work, which showed the rates keep increasing worldwide, particularly throughout the Middle East and South America. The study indicates that obesity and type 2 diabetes function as the main risk components that lead to disease occurrence. The study introduces new knowledge about the diagnostic precision of MRI-PDFF, along with FibroScan, when used as alternative techniques to liver biopsy procedures (Eslam *et al*., 2020). The elevated prevalence numbers in the Middle East region are due to dietary habits and genetic factors, which support the findings of Luukkonen *et al*. (2023) about natural predilection (Zito, 2024). Modern study extends the existing knowledge base by presenting an extensive assessment regarding regional variations, demonstrating the non-invasive diagnostic approaches (Ahmad *et al*., 2022).

The study endeavours to confirm the accuracy of non-invasive biomarkers and imaging techniques for the diagnosis within different demographic groups. The study involving repeated measurements is vital to understanding the lifestyle interventions work for the development of patients who are at high risk of developing NAFLD. A thorough examination of the gut microbiome and genetic factors involved in pathogenesis will help create individual treatment approaches for this disease. Additional study is needed to determine if using GLP-1 receptor agonist drugs could prove beneficial for treating and managing the progression of the disease.

Several weaknesses existed within this study despite its noteworthy results. The analysis depended on published studies using secondary data thus, it might have produced publication biases while studying underdeveloped regions. The outcome quality in different studies demonstrated variations that possibly impacted the analysis's reliability. Differences in the research designs between cross-sectional observations and interventions, together with their observational nature, potentially influenced the compatibility of the analysed data. The analysis of studies published in languages other than English would have expanded the global understanding of NAFLD, since these studies were excluded due to language barriers. The analysis excluded consideration of updated technology in non-invasive diagnostic tools that might have appeared since its review period.

5. Conclusion

The study shows that Non-Alcoholic Fatty Liver Disease affects people worldwide while showing substantial differences between geographical regions. The findings show that the prevalence exceeds its African proportion by breaking the 13% benchmark while reaching 32% representation in the Middle East population, thus revealing that lifestyle habits, alongside genetic tendencies, and medical care availability result in divergent disease outcomes. The strongest contributing elements to NAFLD development were Obesity and type 2 diabetes, alongside PNPLA3 genetic mutations and a high-fat diet. The urgent requirement becomes evident for specific intervention methods that focus on these primary risk elements. The assessment showed that liver biopsy presents as the gold-standard diagnostic approach, but FibroScan, along with MRI-PDFF, deliver effective alternatives for widespread regular monitoring and disease control. The diagnostic techniques demonstrated both high sensitivity and high specificity, which makes them suitable for adoption at a clinical level. Early diagnosis programs with prevention methods demonstrate vital importance, especially for populations prone to high risks. Additional study is required to improve non-invasive biomarkers and therapeutic methods that can stop NAFLD from progressing. The successful management of this requires combined efforts between lifestyle transformation, diagnostic method innovation, and treatment-specific strategies, as it exists as a complex international healthcare concern.

References

1. Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022). Type 2 diabetes. *The Lancet*, *400*(10365), 1803-1820.
2. Anderson, E. L., Howe, L. D., Jones, H. E., Higgins, J. P., Lawlor, D. A., & Fraser, A. (2015). The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. *PloS one*, *10*(10), e0140908.
3. Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., ... & Younossi, Z. (2022). American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and

management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocrine Practice*, *28*(5), 528-562.

4. Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., ... & George, J. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *Journal of hepatology*, *73*(1), 202-209.
5. Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., ... & Razavi, H. (2018). Modelling NAFLD disease burden in China, France, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030. *Journal of hepatology*, *69*(4), 896-904.
6. Gish, R., Fan, J. G., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M., & Boursier, J. (2024). Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. *Hepatology International*, *18*(Suppl 2), 977-989.
7. Gofton, C., & George, J. (2021). Updates in fatty liver disease: Pathophysiology, diagnosis and management. *Australian Journal of General Practice*, *50*(10), 702-707.
8. Hoozemans, J., de Brauw, M., Nieuwdorp, M., & Gerdes, V. (2021). Gut microbiome and metabolites in patients with NAFLD and after bariatric surgery: a comprehensive review. *Metabolites*, *11*(6), 353.
9. Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., ... & Halegoua-DeMarzio, D. (2022). Comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease. *Journal of Cardiovascular Development and Disease*, *9*(12), 419.
10. Luukkonen, P. K., Porthan, K., Ahlholm, N., Rosqvist, F., Dufour, S., Zhang, X. M., ... & Yki-Järvinen, H. (2023). The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. *Cell Metabolism*, *35*(11), 1887-1896.
11. Nakajima, R., Sekiya, M., Furuta, Y., Miyamoto, T., Sato, M., Fukuda, K., ... & Shimano, H. (2022). A case of NASH with genetic predisposition successfully treated with an SGLT2 inhibitor: a possible involvement of mitochondrial dysfunction. *Endocrinology, Diabetes & Metabolism Case Reports*, *2022*(1).
12. Pal, S. C., Eslam, M., & Mendez-Sanchez, N. (2022). Detangling the interrelations between MAFLD, insulin resistance, and key hormones. *Hormones*, *21*(4), 573-589.
13. Singal, A. G., & El-Serag, H. B. (2015). Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. *Clinical gastroenterology and hepatology*, *13* (12), 2140-2151.
14. Softic, S., Cohen, D. E., & Kahn, C. R. (2016). Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. *Digestive diseases and sciences*, *61*, 1282-1293.
15. Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H. U., & White, M. F. (2023). The role of hepatokines in NAFLD. *Cell metabolism*, *35*(2), 236-252.
16. Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2024). Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. *The Lancet Diabetes & Endocrinology*.
17. Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., ... & Floria, M. (2020). The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). *Journal of diabetes research*, *2020*(1), 3920196.
18. Targher, G., Byrne, C. D., & Tilg, H. (2020). NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. *Gut*, *69*(9), 1691-1705.
19. Tsamos, G., Kalopitas, G., Evripidou, K., Vasdeki, D., Koufakis, T., Kanavas, V., ... & Chourdakis, M. (2024). The effects of olive oil consumption on biochemical parameters and body mass index of people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. *Nutrients*, *16*(6), 857.

20. Ub, V., Ks, K., & Pu, V. (2024). Development of multi-particulate formulation of glabridin with L-phenylalanine and its pre-clinical evaluation for anti-obesity activity. *International Journal of Drug Delivery Technology, 14*(1), 183–187. https://doi.org/10.25258/ijddt.14.1.27
21. Uthayakumar, C., & Kotalawala, S. (2021). Impact of Obesity in Non-Alcoholic Fatty Liver Disease. *Journal of Biomedical Science and Engineering*, *14*(2), 21-32.
22. Villard, A., Boursier, J., & Andriantsitohaina, R. (2021). Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, *320*(4), G485-G495.
23. Vos, M. B., Abrams, S. H., Barlow, S. E., Caprio, S., Daniels, S. R., Kohli, R., ... & Xanthakos, S. A. (2017). NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). *Journal of pediatric gastroenterology and nutrition*, *64*(2), 319-334.
24. Younossi, Z., & Henry, L. (2020). The burden of NAFLD worldwide. *Non-Alcoholic Fatty Liver Disease: A 360-degree Overview*, 15-24.
25. Zito, R. (2024). Liver Transcriptome Analysis in NAFLD Patients.